# US 2021/0341484 A1 · Methods for Detecting Cancer-Related Cell Populations, Screening for Metastatic Cancer and Treatments Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341484 A1
- Document ID: US20210341484A1
- Status: Published application
- Kind: A1
- Application number: 17/255,118
- Filed: 2019-07-01
- Published: 2021-11-04
- Earliest claimed: 2018-07-02
- Assignees: IncellDx, Inc.
- Applicants: IncellDx, Inc.
- Inventors: Bruce K. Patterson; Amanda Noel Chargin; Xiaoyang Wang; Pin-I Chen
- Web page: https://patentgrep.com/patent/US20210341484A1

## CPC

- A61P 35/00: Antineoplastic agents
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 15/14: Optical investigation techniques, e.g. flow cytometry
- G01N 15/1459: {the analysis being performed on a sample stream}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 2015/1006: {for cytology}
- G01N 2015/1402: {Data analysis by thresholding or gating operations performed on the acquired signals or stored data}
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- G01N 2333/70514: CD4
- G01N 2333/70517: CD8
- G01N 2333/70521: CD28, CD152
- G01N 2333/70535: Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/7158: for chemokines
- G01N 2800/7028: Cancer
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are methods involving the assaying of a labeled cell suspension, e.g., to detect cancer-related cells, populations ON thereof and/or screen for metastatic cancer. Labeled cell suspensions may be assayed to detect whether a tumor infiltrating lymphocyte (TIL) population is present in a cellular suspension of a subject. Cancer-related cell populations of interest include, e.g., those expressing one or more markers, including where the markers are members of a marker panel. Markers assayed may vary depending on the context and may include protein markers, nucleic acid markers, cell cycle markers, DNA content markers, and the like. Useful markers include one or more immune checkpoint markers and/or one or more immune cell-type markers, including where the marker(s) assayed are part of one or more panels of markers. Also provided are methods of treating a subject for a neoplasia based on the outcome of an assay of a labeled cell suspension of sample from a subject. Kits for practicing the described methods are also provided.

## Claims

### Claim 1

A method comprising:
contacting a cellular suspension prepared from a biopsy collected from a tumor in a subject with:
an immune checkpoint panel comprising a plurality of detectable immune checkpoint marker binding members; and
an immune cell-type panel comprising a plurality of detectable immune cell-type marker binding members,
to produce a labeled cell suspension; and
cytometrically assaying the labeled cell suspension to detect whether a tumor infiltrating lymphocyte (TIL) population expressing an immune checkpoint marker of the immune checkpoint panel and an immune cell-type marker of the immune cell-type panel is present in the cellular suspension.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the plurality of detectable immune cell-type marker binding members comprises specific binding members for two or more immune checkpoint markers selected from the group consisting of: programmed cell death 1 (PD-1), T-cell immunoglobulin mucin receptor 3 (TIM-3), lymphocyte-activation gene-3 (LAG-3) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4).

### Claim 3 (depends on 1)

The method according to claim 1, wherein the plurality of detectable immune cell-type marker binding members comprises specific binding members for two or more immune cell-type markers selected from the group consisting of CD3, CD4, CD8, CD16, CD19, CD25, CD56, CD127 and CCR5.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method comprises cytometrically assaying the cellular suspension to determine whether two or more different TIL populations are present in the cellular suspension.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the immune cell-type panel further comprises a detectable binding member specific for an immune activation marker and/or an adhesion-related marker.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the method further comprises dissociating the biopsy, or a sample therefrom, to prepare the cellular suspension.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the dissociating comprises non-enzymatic tissue homogenization.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the cellular suspension is further contacted with a fixation reagent.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the biopsy is a solid tissue biopsy.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the tumor is a lung cancer tumor.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the lung cancer tumor is a non-small cell lung cancer (NSCLC) tumor.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the cellular suspension is further contacted with a DNA staining reagent.

### Claim 13

A kit comprising:
an immune checkpoint panel comprising a plurality of detectable immune checkpoint marker binding members; and
an immune cell-type panel comprising a plurality of detectable immune cell-type marker binding members.

### Claim 14 (depends on 1)

A method of screening a subject for metastatic cancer, the method comprising:
detecting the presence of the TIL population according to the method of claim 1; and
testing the subject for a metastatic cancer based on the detected presence of the TIL population.

### Claim 15 (depends on 1)

A method of treating a subject for a neoplasia, the method comprising:
detecting the presence or absence of the TIL population according to the method of claim 1; and
treating the subject for the neoplasia, wherein the treating comprises:
a systemic treatment for the neoplasia when the TIL population is detected to be present; or
a local treatment for the neoplasia when the TIL is detected to be absent.
